The estimated Net Worth of Jeffrey A Meckler is at least $264 millier dollars as of 28 August 2019. Mr. Meckler owns over 20,000 units of Retrophin stock worth over $13,773 and over the last 10 years he sold RTRX stock worth over $0. In addition, he makes $250,150 as Independent Director at Retrophin.
Jeffrey has made over 9 trades of the Retrophin stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of RTRX stock worth $13,600 on 28 August 2019.
The largest trade he's ever made was buying 294,118 units of Retrophin stock on 15 March 2016 worth over $150,000. On average, Jeffrey trades about 40,358 units every 87 days since 2014. As of 28 August 2019 he still owns at least 196,761 units of Retrophin stock.
You can see the complete history of Mr. Meckler stock trades at the bottom of the page.
Jeffrey A. Meckler is an Independent Director of the Company. Since April 2017, Mr. Meckler has served as Chief Executive Officer and Vice Chairman of the Board of Intec Pharma, Ltd., a pharmaceutical company. He served as Chief Executive Officer and a director of CoCrystal Pharma, Inc., a pharmaceutical company, from April 2015 to July 2016, as a director of QLT, Inc., an ultra-orphan opthalmic biotechnology company based in Canada, from June 2012 to November 2016, as well as the Managing Director of The Andra Group, a life sciences consulting firm. From January 2011 to September 2012, Mr. Meckler acted as a director and Interim Chief Executive Officer of Cypress Bioscience Inc. after its acquisition by Royalty Pharma. He has also served as a director of ClearFarma USA, Kyalin Bioscience and Alveolus Inc. Earlier in his career, Mr. Meckler held a series of positions at Pfizer Inc. in Manufacturing Systems, Market Research, Business Development, Strategic Planning and Corporate Finance, which included playing a significant role in acquisitions and divestitures. Mr. Meckler is the past President and continues to serve on the board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in Industrial Management and M.S. in Industrial Administration from Carnegie Mellon University. In addition, Mr. Meckler received a J.D. from Fordham University School of Law.
As the Independent Director of Retrophin, the total compensation of Jeffrey Meckler at Retrophin is $250,150. There are 10 executives at Retrophin getting paid more, with Eric Dube having the highest compensation of $9,679,320.
Jeffrey Meckler is 53, he's been the Independent Director of Retrophin since 2014. There are 8 older and 3 younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.
Jeffrey's mailing address filed with the SEC is C/O INTEC PHARMA LTD., 12 HARTOM STREET, JERUSALEM, L3, 9777512.
Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer et Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Retrophin executives and other stock owners filed with the SEC include: